Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
TARGET 2
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome
1 other identifier
interventional
637
1 country
88
Brief Summary
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Jul 2008
Shorter than P25 for phase_3
88 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2008
CompletedFirst Submitted
Initial submission to the registry
July 26, 2008
CompletedFirst Posted
Study publicly available on registry
July 29, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2009
CompletedResults Posted
Study results publicly available
July 28, 2014
CompletedNovember 29, 2019
November 1, 2019
1.1 years
July 26, 2008
June 30, 2014
November 26, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).
The primary outcome measure is assessed during the 4-week period (ie, Weeks 3 through 6) immediately following 2 weeks of treatment with study drug. Adequate relief of global IBS symptoms was defined as a response of "yes" to the following question, which was asked weekly (every 7 days): "In regard to all your symptoms of IBS, as compared to the way you felt before you started study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms? \[Yes/No\]"
4 weeks
Secondary Outcomes (1)
Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6)
4 weeks
Study Arms (2)
Placebo
PLACEBO COMPARATORSubjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
Rifaximin
EXPERIMENTALSubjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
Interventions
Eligibility Criteria
You may qualify if:
- Confirmed IBS diagnosis per Rome II criteria for diagnosis of IBS.
- Colonoscopy within 2 years as part of IBS diagnostic evaluation.
- Has active symptoms of non-constipation IBS at baseline as measured by average daily scores for abdominal pain/discomfort, bloating, and stool consistency.
You may not qualify if:
- Symptoms of constipation.
- History of other gastrointestinal diseases.
- Type 1 or 2 diabetes.
- Lactose intolerance not controlled by lactose-free diet.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (88)
Unknown Facility
Anniston, Alabama, 36207, United States
Unknown Facility
Birmingham, Alabama, 35205, United States
Unknown Facility
Huntsville, Alabama, 35801, United States
Unknown Facility
Tempe, Arizona, 85282, United States
Unknown Facility
Anaheim, California, 92801, United States
Unknown Facility
Carmichael, California, 95608, United States
Unknown Facility
Chula Vista, California, 91910, United States
Unknown Facility
Concord, California, 94520, United States
Unknown Facility
Garden Grove, California, 92840, United States
Unknown Facility
Laguna Hills, California, 92653, United States
Unknown Facility
Lakewood, California, 90712, United States
Unknown Facility
Los Angeles, California, 90048, United States
Unknown Facility
Monterey, California, 93940, United States
Unknown Facility
Orange, California, 92868, United States
Unknown Facility
Roseville, California, 95661, United States
Unknown Facility
San Carlos, California, 94070, United States
Unknown Facility
San Francisco, California, 94117, United States
Unknown Facility
Bristol, Connecticut, 06010, United States
Unknown Facility
Hamden, Connecticut, 06518, United States
Unknown Facility
Newark, Delaware, 19713, United States
Unknown Facility
Boca Raton, Florida, 33486, United States
Unknown Facility
Hollywood, Florida, 33021, United States
Unknown Facility
Largo, Florida, 33777, United States
Unknown Facility
New Port Richey, Florida, 34655, United States
Unknown Facility
New Smyrna Beach, Florida, 32168, United States
Unknown Facility
Port Orange, Florida, 32127, United States
Unknown Facility
St. Petersburg, Florida, 33709, United States
Unknown Facility
Tampa, Florida, 33607, United States
Unknown Facility
Zephyrhills, Florida, 33542, United States
Unknown Facility
Atlanta, Georgia, 30342, United States
Unknown Facility
Macon, Georgia, 31201, United States
Unknown Facility
Elkhart, Indiana, 46514, United States
Unknown Facility
Kansas City, Kansas, 66160, United States
Unknown Facility
Topeka, Kansas, 66606, United States
Unknown Facility
Bowling Green, Kentucky, 42104, United States
Unknown Facility
Metairie, Louisiana, 70006, United States
Unknown Facility
Monroe, Louisiana, 71201, United States
Unknown Facility
Baltimore, Maryland, 21229, United States
Unknown Facility
Elkridge, Maryland, 21075, United States
Unknown Facility
Wellesley, Massachusetts, 02481, United States
Unknown Facility
Ann Arbor, Michigan, 48109, United States
Unknown Facility
Troy, Michigan, 48098, United States
Unknown Facility
Wyoming, Michigan, 49519, United States
Unknown Facility
Mexico, Missouri, 65265, United States
Unknown Facility
Sicklerville, New Jersey, 08081, United States
Unknown Facility
Voorhees Township, New Jersey, 08043, United States
Unknown Facility
Albuquerque, New Mexico, 87102, United States
Unknown Facility
Great Neck, New York, 11021, United States
Unknown Facility
Mineola, New York, 11501, United States
Unknown Facility
New York, New York, 10016, United States
Unknown Facility
North Massapequa, New York, 11758, United States
Unknown Facility
Pomona, New York, 10970, United States
Unknown Facility
Stony Brook, New York, 11790, United States
Unknown Facility
Boone, North Carolina, 28607, United States
Unknown Facility
Chapel Hill, North Carolina, 27514, United States
Unknown Facility
Charlotte, North Carolina, 28209, United States
Unknown Facility
Greensboro, North Carolina, 27403, United States
Unknown Facility
Greensboro, North Carolina, 27408, United States
Unknown Facility
New Bern, North Carolina, 28562, United States
Unknown Facility
Wilmington, North Carolina, 28401, United States
Unknown Facility
Winston-Salem, North Carolina, 27103, United States
Unknown Facility
Canton, Ohio, 44718, United States
Unknown Facility
Cincinnati, Ohio, 45242, United States
Unknown Facility
Dayton, Ohio, 45415, United States
Unknown Facility
Downingtown, Pennsylvania, 19335, United States
Unknown Facility
Newtown, Pennsylvania, 18940, United States
Unknown Facility
Pittsburgh, Pennsylvania, 15206, United States
Unknown Facility
Sayre, Pennsylvania, 18840, United States
Unknown Facility
Anderson, South Carolina, 29621, United States
Unknown Facility
Columbia, South Carolina, 29203, United States
Unknown Facility
Bristol, Tennessee, 37620, United States
Unknown Facility
Chattanooga, Tennessee, 37421, United States
Unknown Facility
Franklin, Tennessee, 37067, United States
Unknown Facility
Germantown, Tennessee, 38138, United States
Unknown Facility
Jackson, Tennessee, 38301, United States
Unknown Facility
Kingsport, Tennessee, 37660, United States
Unknown Facility
El Paso, Texas, 79902, United States
Unknown Facility
Houston, Texas, 77024, United States
Unknown Facility
Lewisville, Texas, 75057, United States
Unknown Facility
Plano, Texas, 75075, United States
Unknown Facility
San Antonio, Texas, 78229, United States
Unknown Facility
Salt Lake City, Utah, 84107, United States
Unknown Facility
Burlington, Vermont, 05401, United States
Unknown Facility
Chesapeake, Virginia, 23320, United States
Unknown Facility
Fairfax, Virginia, 22031, United States
Unknown Facility
Spokane, Washington, 99208, United States
Unknown Facility
Milwaukee, Wisconsin, 53215, United States
Unknown Facility
Milwaukee, Wisconsin, 53226, United States
Related Publications (3)
Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011 Jan 6;364(1):22-32. doi: 10.1056/NEJMoa1004409.
PMID: 21208106RESULTLacy BE, Chang L, Rao SSC, Heimanson Z, Sayuk GS. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points. Clin Ther. 2023 Mar;45(3):198-209. doi: 10.1016/j.clinthera.2023.01.010. Epub 2023 Mar 14.
PMID: 36922331DERIVEDSchoenfeld P, Pimentel M, Chang L, Lembo A, Chey WD, Yu J, Paterson C, Bortey E, Forbes WP. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014 May;39(10):1161-8. doi: 10.1111/apt.12735. Epub 2014 Apr 3.
PMID: 24697851DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- David Sorscher
- Organization
- Salix
Study Officials
- STUDY DIRECTOR
Enoch Bortey
Bausch Health Americas, Inc.
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- GT60
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 26, 2008
First Posted
July 29, 2008
Study Start
July 1, 2008
Primary Completion
August 1, 2009
Study Completion
September 1, 2009
Last Updated
November 29, 2019
Results First Posted
July 28, 2014
Record last verified: 2019-11